Simon Property Group Inc vs Vir Biotechnology Inc. Common Stock — how do they compare? Simon Property Group Inc trades at $201.65 (market cap $64.29B), while Vir Biotechnology Inc. Common Stock trades at $10.49 (market cap $1.76B). The key difference: Simon Property Group Inc is far larger — about 36.5× Vir Biotechnology Inc. Common Stock's market cap, and Simon Property Group Inc pays a 4.48% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Simon Property Group Inc for 100 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| SPG | VIR | |
|---|---|---|
Market Cap | $64.29B | $1.76B |
Volume | 1,236,199 | 2,764,948 |
Sector | Real Estate | Health |
52-Week High | $236.70 | $11.78 |
52-Week Low | $173.35 | $5.12 |
Typical Hold Time | 100 Days | 0 Days |
Enterprise Value | $92.74B | $1.32B |
Dividend Yield | 4.48% | — |
Signals from Pluang's Aura AI — not financial advice
Simon Property Group (SPG) trades at $200.65, down 0.38% with bearish technical signals. The REIT shows strong fundamentals with 2025 revenue of $6.36B, net income of $4.63B (72.7% margin), and attractive valuation at 14.16 P/E. Recent earnings show mixed results with Q2 2026 missing expectations. The company maintains strong leasing demand and recently launched Simon Media Network to monetize mall traffic.
SPG offers value with solid dividend yield and double-digit return potential, though faces headwinds from rising bond yields and $2B debt maturities in 2024. Analyst consensus at $218.45 target suggests 8.9% upside, supported by accelerating NOI growth and A-rated balance sheet strength.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →